Rivaroxaban (Xarelto, BAY59-7939) + Apixaban (Eliquis) + Dabigatran etexilate (Pradaxa) + Warfarin (Marevan)

Pre-clinicalTerminated

0 views this week 0 watching💤 Quiet

Interest: 15/100

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Non-valvular Atrial Fibrillation

Conditions

Non-valvular Atrial Fibrillation

Trial Timeline

Oct 31, 2018 → Jan 20, 2020

NCT ID

NCT03715725

About Rivaroxaban (Xarelto, BAY59-7939) + Apixaban (Eliquis) + Dabigatran etexilate (Pradaxa) + Warfarin (Marevan)

Rivaroxaban (Xarelto, BAY59-7939) + Apixaban (Eliquis) + Dabigatran etexilate (Pradaxa) + Warfarin (Marevan) is a pre-clinical stage product being developed by Bayer for Non-valvular Atrial Fibrillation. The current trial status is terminated. This product is registered under clinical trial identifier NCT03715725. Target conditions include Non-valvular Atrial Fibrillation.

What happened to similar drugs?

2 of 3 similar drugs in Non-valvular Atrial Fibrillation were approved

Approved (2) Terminated (0) Active (1)

✅Edoxaban + Aspirin and Clopidogrel + Aspirin and WarfarinDaiichi SankyoApproved

✅ApixabanBristol Myers SquibbApproved

🔄DU-176b 15mg + DU-176b 30mg + DU-176b 60mgDaiichi SankyoPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03715725	Pre-clinical	Terminated	Oct 31, 2018	Jan 20, 2020	Non-valvular Atrial Fibrillation

Competing Products

17 competing products in Non-valvular Atrial Fibrillation

See all competitors

Product	Company	Stage	Hype Score
Edoxaban	Daiichi Sankyo	Pre-clinical	26
DU-176b 15mg + DU-176b 30mg + DU-176b 60mg	Daiichi Sankyo	Phase 3	40
Edoxaban + Aspirin and Clopidogrel + Aspirin and Warfarin	Daiichi Sankyo	Approved	39
Edoxaban	Daiichi Sankyo	Pre-clinical	26
AZD0837 + Aspirin	AstraZeneca	Phase 2	35
Apixaban + Warfarin	Pfizer	Pre-clinical	26
Warfarin + Apixaban	Pfizer	Pre-clinical	26
Apixaban	Bristol Myers Squibb	Approved	43
Apixaban	Bristol Myers Squibb	Pre-clinical	18
Rivaroxaban (Xarelto, BAY59-7939)	Bayer	Pre-clinical	23
Rivaroxaban(Xarelto,BAY 59-7939)	Bayer	Pre-clinical	23
Rivaroxaban (Xarelto,Bay 59-7939)	Bayer	Pre-clinical	23
Rivaroxaban (Xarelto, BAY59-7939) + Warfarin	Bayer	Pre-clinical	23
Rivaroxaban (Xarelto, BAY-597939) + VKAs	Bayer	Pre-clinical	23
Non-VKA Oral Anticoagulants (NOAC)	Bayer	Pre-clinical	23
Rivaroxaban (Xarelto, BAY59-7939)	Bayer	Pre-clinical	23
Rivaroxaban (Xarelto_ BAY59-7939)	Bayer	Pre-clinical	23